Answers are grounded in this paper and cite their sources.
Objectives: To evaluate the accuracy and clinical utility of GPT-4O in recognizing abnormal blood cell morphology, a critical component of hematologic diagnostics. Methods: GPT-4O's blood cell morphology recognition capabilities were assessed by comparing its performance with hematologists. A total of 70 images from the Chinese National Center for Clinical Laboratories, External Quality Assessment (EQA) from 2022 to 2024 were analyzed. Two experienced hematology experts evaluated GPT-4O's recognition accuracy using a Likert scale. Results: GPT-4O achieved an overall accuracy of 70% in blood cell morphology recognition, significantly lower than the 95.42% accuracy of hematologists (p < 0.05). For peripheral blood smears and bone marrow smears, GPT-4O's accuracy was 77.14% and 62.86% respectively. Likert scale evaluations revealed further discrepancies, with GPT-4O scoring 288.50 out of 350, compared to higher manual scores. GPT-4O accurately recognized certain intracellular inclusions such as Howell-Jolly bodies and Auer rods, while it misidentified fragmented red blood cells as neutrophilic metamyelocytes and oval-shaped red blood cells as sickle cells. Additionally, GPT-4O had difficulty accurately identifying intracellular granules and distinguishing cell nuclei and cytoplasm. Conclusion: GPT-4O's performance in recognizing abnormal blood cell morphology is currently inadequate compared to hematologists. Despite its potential as a supplementary tool, significant improvements in its recognition algorithms and an expanded dataset are necessary for it to be reliable for clinical use. Future research should focus on enhancing GPT-4O's diagnostic accuracy and addressing its current limitations.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: